反应详情

To a solution of [4-(2-{(1S,2R)-2-[1-(5-chloropyrimidin-2-yl)piperidin-4-yl]cyclopropyl}ethoxy)-2-fluorophenyl]acetic acid (100 mg, 0.230 mmol) in 1 ml of anhydrous DMF at RT was added azetidine (13.2 mg, 0.230 mmol) and N,N-diisopropylethylamine (0.201 ml, 1.15 mmol). o-(7-Azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (175 mg, 0.461 mmol) was added to the solution and the mixture stirred at RT for 4 hrs. The mixture was filtered and purified by reverse-phase HPLC (SunFire Prep C18 OBD 5 um 19×100 mm column; 35-75% acetonitrile in 0.1% formic acid in water gradient) to give the title compound. LC/MS (m/z): 473.1 (M+H)+. GPR119 Human EC50: 0.19 nM

1. filtrationThe mixture was filtered
2. custompurified by reverse-phase HPLC (SunFire Prep C18 OBD 5 um 19×100 mm column; 35-75% acetonitrile in 0.1% formic acid in water gradient)